Voltar
Artigo Revisado por pares
BIBTEX RIS

P-389 Phase 3, Two-stage, Randomized Trials of Mezigdomide-Based Regimens Versus Standard Regimens in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1 (MeziVd vs PVd) and SUCCESSOR-2 (MeziKd vs Kd)

2024; Elsevier BV; Volume: 24; Linguagem: Inglês

10.1016/s2152-2650(24)02291-2

ISSN

2152-2650

Autores

Meletios Α. Dimopoulos, Sorina Bădeliță, Fredrik Schjesvold, Hang Quach, Chang‐Ki Min, Ja Min Byun, César Cinesi Gómez, Chengcheng Fu, Bradley Augustson, Vânia Hungria, Edvan de Queiroz Crusoé, Donna Reece, Nishi Shah, Thomas Chalopin, Moshe E. Gatt, Olga Motorna, Anna Wiksten, Ze‐Hua Zhou, Joshua Emerson, Brian Yu, Soo Jeong Hwang, Brian G. Engelhardt, Alberto Rocci, Jessica Katz, Paul L. Richardson,

Tópico(s)

Peptidase Inhibition and Analysis

Referência(s)